文献速递头颈部肿瘤放疗放疗物理与技术

ESCALOX试验预研究:VMAT、IMRT与螺旋断层放疗计划比较报告

Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study.
PubMed 文献 · Radiat Oncol · 2020-11-02

ESCALOX试验为头颈癌多中心随机前瞻性剂量递增研究,预研究比较6例口咽癌患者(均男性,平均年龄61.3岁)的IMRT、VMAT与螺旋断层放疗(HT)计划。三步SIB(77 Gy、70 Gy、56 Gy)归一化为D95%=77 Gy,各技术均达到良好覆盖,HT在覆盖、适形与均匀性方面表现良好,IMRT与VMAT结果也可接受。

要点

  • 三种放疗技术均实现良好靶区覆盖,剂量递增计划质量可靠。
  • SIB77Gy时HT的CN最高,IMRT与VMAT的CVF最佳。
  • 双侧腮腺Dmean以HT更优,IMRT与VMAT结果可接受。

核心结论

  • 不同治疗计划系统用于剂量递增均可靠达到高质量计划。
  • HT在覆盖、适形与均匀性方面结果很好,IMRT与VMAT也可接受。

研究设计与样本

  • ESCALOX预研究采用前6例口咽癌患者(均男性,平均年龄61.3岁)的CT数据集。
  • 比较IMRT、VMAT与螺旋断层放疗(HT)计划,剂量递增至77 Gy。
  • 三步SIB为77 Gy、70 Gy、56 Gy,归一化为D95%=77 Gy。

主要发现

  • 所有放疗技术均达到良好覆盖。
  • SIB77Gy:CVF以IMRT和VMAT最佳,CN以HT最高、其后为VMAT和IMRT。
  • SIB70Gy:CVF以IMRT最佳,HTCI与CN均以HT更优,HI以HT略好。
  • SIB56Gy:CVF结果相当,HTCI与CN显示适形性以VMAT更优。
  • 同侧与对侧腮腺Dmean以HT更优。

临床怎么用

  • 头颈癌剂量递增SIB计划可基于不同TPS与RT技术实现,HT、IMRT与VMAT均可获得可接受的计划质量。

局限性

  • 预研究仅基于前6例患者的数据集,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ESCALOX trial was designed as a multicenter, randomized prospective dose escalation study for head and neck cancer. Therefore, feasibility of treatment planning via different treatment planning systems (TPS) and radiotherapy (RT) techniques is essential. We hypothesized the comparability of dose distributions for simultaneous integrated boost (SIB) volumes respecting the constraints by different TPS and RT techniques. METHODS: CT data sets of the first six patients (all male, mean age: 61.3 years) of the pre-study (up to 77 Gy) were used for comparison of IMRT, VMAT, and helical tomotherapy (HT). Oropharynx was the primary tumor location. Normalization of the three step SIB (77 Gy, 70 Gy, 56 Gy) was D95% = 77 Gy. Coverage (CVF), healthy tissue conformity index (HTCI), conformation number (CN), and dose homogeneity (HI) were compared for PTVs and conformation index (COIN) for parotids. RESULTS: All RT techniques achieved good coverage. For SIB77Gy, CVF was best for IMRT and VMAT, HT achieved highest CN followed by VMAT and IMRT. HT reached good HTCI value, and HI compared to both other techniques. For SIB70Gy, CVF was best by IMRT. HTCI favored HT, consequently CN as well. HI was slightly better for HT. For SIB56Gy, CVF resulted comparably. Conformity favors VMAT as seen by HTCI and CN. Dmean of ipsilateral and contralateral parotids favor HT. CONCLUSION: Different TPS for dose escalation reliably achieved high plan quality. Despite the very good results of HT planning for coverage, conformity, and homogeneity, the TPS also achieved acceptable results for IMRT and VMAT. Trial registration ClinicalTrials.gov Identifier: NCT01212354, EudraCT-No.: 2010-021139-15. ARO: ARO 14-01.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pigorsch SU, Kampfer S, Oechsner M, et al. Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study. Radiat Oncol. 2020. PMID: 33138837. doi:10.1186/s13014-020-01693-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。